Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250437 | 0.79 | CES2 (0.39) | GSK3BCES2 | |
| SCHEMBL2784786 | 0.79 | GSK3B (0.41) | GSK3BCES2CES1ACP3PDE2A | |
| SCHEMBL4963831 | 0.79 | TSHR (0.47) | CYP1A2ALDH1A1TSHR | |
| SCHEMBL22800995 | 0.79 | TSHR (0.47) | CYP1A2ALDH1A1TSHR | |
| SCHEMBL5185160 | 0.78 | CES2 (0.46) | GSK3BCES2CES1ACP3PDE2A | |
| SCHEMBL15333298 | 0.78 | CES2 (0.46) | GSK3BCES2CES1ACP3PDE2A | |
| SCHEMBL40176 | 0.77 | ACP3 (0.47) | CES2ACP3TSHRFBP1 | |
| SCHEMBL11320769 | 0.77 | CES2 (0.44) | GSK3BCES2CES1ACP3PDE2A | |
| SCHEMBL16601182 | 0.76 | OPRD1 (0.36) | PDE2AHSD11B1TSHR | |
| SCHEMBL168223 | 0.76 | IDO1 (0.38) | CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| US-20200048205-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3544980-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-10-02 | — | — | EP | disclosed |
| EP-3475276-A1 | THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3362446-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | Indivior UK Limited (GB) | 2018-08-22 | — | — | EP | disclosed |
| WO-2018098411-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-3325471-A1 | COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS | Genzyme Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3283464-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017223202-A1 | THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-3237385-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2007099548-A2 | NOVEL 11 BETA - HYDROXYANDROSTA-4-ENE-3-ONES | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007089557-A2 | POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007056366-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056496-A1 | OXAZOLE AND THIAZOLE PPAR MODULATOR | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006122250-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006057503-A1 | NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LG LIFE SCIENCES, LTD. (KR) | 2006-06-01 | — | — | WO | disclosed |
| WO-2003055479-A1 | COMPOUNDS AND THEIR THERAPEUTIC USE RELATED TO THE PHOSPHORYLATING ACTIVITY OF THE ENZYME GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2003-07-10 | — | — | WO | disclosed |
| EP-1194144-A4 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1194144-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000071120-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048205-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR2C | GSK3B 1376/4885CES2 1755/4885CES1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.